Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Studies from M. Tejeda and co-researchers update current data on breast cancer
January 8th, 2009
According to a study from Budapest, Hungary, "The somatostatin structural derivative, TT-232, has a special 5-residue ring structure (D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH2) and very different characteristics from the known growth hormone (GH) active somatostatin analogs. This somatostatin structural derivative has no GH release inhibitory or antisecretory activity and does not bind to rat pituitary or the cortex, where all the known somatostatin receptor subtypes are expressed." "TT-232 had previously been shown to inhibit the proliferation of a large number of cancer cell lines in, vitro and reduce the size of different tumors in animal models in vivo. The therapeutic...
Source: Women's Health Weekly (2009-01-08)
|
